Can a picture tell a RA swollen joint? (would be super useful for telehealth/remote monitor if so) It's not prime time yet, but following with interest: using photos to pick up on skin folds/joint swelling Fascinating, but let's see it vs MRI, clinical #ACR23 ABST0402 @RheumNow https://t.co/TFKiD5J4c8

We gotta do better! Reproductive health counseling is poorly done- only a third rheumatologists surveyed ask pts about reproductive health: sexual activity, pregnancy desire, contraception. Abstr#0162 @_michgarcia @rheumnow #ACR23 https://t.co/r9tewu2I9N

Smartwatches to measures axSpA activity? Upadacitinib use in axSpA INCREASED physical activity based on a wearable medical device step count, especially in those who were originally sedentary. @RheumNow #ACR23 Abs#0530 #ACRbest https://t.co/oOFiQwMFZ6

SLE pts with +aCL IgG/IgM and LA had higher risk of developing atherosclerotic CVD accdg to this prospective study by Ding et al. . . . 🧐Again, SLE pts have ⬆️CV risk so always risk stratify and intervene early. #ACR23 ABST0552 @RheumNow https://t.co/QhttQZzp8G

Year in Review by Dr. P Seo NORD-STAR trial: ⭐️Abatacept or Certolizumab >> Tociluzumab > triple therapy in tx of 812 early RA patients based on clinical & radiographic results ➡️tx-naive, all got MTX ➡️mod-sev dz activity ➡️randomized to 48 wks therapy #ACR23 @RheumNow https://t.co/vy2uYuyOse

Interesting question... but feels like some time related bias or perhaps confounding? Seems implausible that MTX & biologic would be protective for PsO & harmful for PsA @RheumNow #ACR23 Abstr 0498 https://t.co/pSRoLHRTAm

NAFLD a real issue in RA Does DMARD choice matter? National Taiwanese data newly dx RA n=41791 HCQ reduced NAFLD risk: adjHR 0.75 (other RF: obesity, NSAIDs, even low-dose PNL; but not DM, MTX) Can HCQ improve liver health in RA? Authors: ?adiponectin #ACR23 ABST0396 @RheumNow https://t.co/9VMJpImFKs

C-VIEW study on certolizumab use in preventing anterior uveitis in high risk pts with axSpA. All pts were B27+ w/ at least one episode of anterior uveitis Uveitis flares lower in certolizumab group compared to non-bDMARD use @RheumNow #ACR23 Abs#0524 https://t.co/CfnhzStBMv

This study by Munoz-Grajales et al show that the analyte S100A8/A9 (highest AUC) was able to differentiate between SLE pts with cognitive impairment and those without. . . . Interesting findings. More data needed to confirm and explain why it is so. #ACR23 ABST0558 @RheumNow https://t.co/LcF6s2qgNr

PROs are useful for tracking RA disease activity over time outside of the clinic setting for patients initiating new treatments without clinician-derived measures. Correlations in follow-up CDAI and PROs were 0.38 – 0.56, Nowell Abst#0380 #ACR23 @RheumNow https://t.co/LepCZ7sPY8 https://t.co/UYcZzIFEsx

#CV risk in #AxSpA in Korean population study N=71001, age 42, 71%M but 16% #MTX, 58% #SSZ. #TNFi vs none 30% less CVE. IL17 NO CV reduction but ?confounded by line of #Rx and v large N for TNFi. Study stated PRIOR to IL17i approval #ACR23 @ACRheum @RheumNow L11 poster ?Rx bias https://t.co/3Sft5KUlLa

Nice VA study evaluating risk of lung cancer w/respect to RA treatment strategies Take home? No association. Aside from the (small risk) w/JAKi's, I think malignancy risks have been mostly overblown @NamrataRheum @RheumNow ABST0453 #ACR23 https://t.co/lDz0nV1KHt